References
- World Health Organization. (2011) WHO Report: Global Tuberculosis Control, 2011 [cited Acess on 2014 28Mar]. Available from: http://www.who.int/tb/en/.
- Tessema B, Muche A, Bekele A, et al. Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. A five–year retrospective study. BMC Public Health. 2009;9:371.
- Chiang CY, Lee JJ, Yu MC, et al. Tuberculosis outcomes in Taipei: factors associated with treatment interruption for 2 months and death. Int J Tuberc Lung Dis. 2009;13:105–111.
- Pablos-Mendez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996;276:1223–1228.
- Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14:454–463.
- Silva DR, Menegotto DM, Schulz LF, et al. Factors associated with mortality in hospitalized patients with newly diagnosed tuberculosis. Lung 2010;188:33–41.
- Jeng YY, Lin YT, Huang LJ, et al. Does radiographic evidence of prior pulmonary tubercular infection influence the choice of empiric antibiotics for community-acquired pneumonia in a tuberculosis-endemic area? J Microbiol Immunol Infect. 2010;43:386–394.
- Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34:1607–1612.
- Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006;10:605–612.
- Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 1997;156:901–905.
- Luna-Herrera JRV, Daneluzzi D, Gangadharam PR. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother. 1995;39:2692–2695.
- Chambers HF, Moreau D, Yajko D, et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother. 1995;39:2620–2624.
- Chambers HF, Kocagoz T, Sipit T, et al. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis. 1998;26:874–877.
- Chen TC, Lu PL, Lin CY, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011;15:e211–e216.
- Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006;61:903–908.
- Yoon YS, Lee HJ, Yoon HI, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis. 2005;9:1215–1219.
- Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis. 2009;48:1354–1360.
- Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009;180:365–370.
- van der Heijden YF, Maruri F, Blackman A, et al. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis. 2012;16:1162–1167.
- Wang M, Fitzgerald JM, Richardson K, et al. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic? Int J Tuberc Lung Dis. 2011;15:1062–1068.
- Golub JE, Bur S, Cronin WA, et al. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis. 2005;9:392–397.
- Tseng YTCY, Shu CC, Hung CC, et al. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia. Crit Care. 2012;16:R207.
- Shen GH, Tsao TC, Kao SJ, et al. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents. 2012;39:201–205.
- Chen L, Yip W, Chang MC, et al. The effects of Taiwan's National Health Insurance on access and health status of the elderly. Health Econ. 2007;16:223–242.
- Guidelines on Antimicrobial Therapy of Pneumonia in Adults in Taiwan, Revised 2006. Infectious diseases society of Taiwan; Taiwan society of pulmonary and critical medicine. J Microbiol Immunol Infect. 2007;40:279–283.
- Hagan G, Nathani N. Clinical review: tuberculosis on the intensive care unit. Crit Care. 2013;17:240.
- Ryu YJ, Koh WJ, Kang EH, et al. Prognostic factors in pulmonary tuberculosis requiring mechanical ventilation for acute respiratory failure. Respirology. 2007;12:406–411.
- Lee PL, Jerng JS, Chang YL, et al. Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation. Eur Respir J. 2003;22:141–147.
- Penner C, Roberts D, Kunimoto D, et al. Tuberculosis as a primary cause of respiratory failure requiring mechanical ventilation. Am J Respir Crit Care Med. 1995;151:867–872.
- Kim YJ, Pack KM, Jeong E, et al. Pulmonary tuberculosis with acute respiratory failure. Eur Respir J. 2008;32:1625–1630.
- Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009;373:1183–1189.
- Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12:128–138.
- Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371:1577–1587.
- Zahar JR, Azoulay E, Klement E, et al. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med. 2001;27:513–520.
- Thomas R Frieden JAS, Bulletin of the World Health Organization. Promoting adherence to treatment for tuberculosis: the importance of direct observation [Internet]; [cited 2016 Mar 21]. Available from: http://www.who.int/bulletin/volumes/85/5/06-038927/en/.
- Bloss ECP, Cheng NW, Wang KF, et al. Increasing directly observed therapy related to improved tuberculosis treatment outcomes in Taiwan. Int J Tuberc Lung Dis. 2012;16:462–467.
- Yen YFYM, Lin YP, Shih HC, et al. Directly observed therapy reduces tuberculosis-specific mortality: a population-based follow-up study in Taipei, Taiwan. PLoS One. 2013;8:e79644.